Johanna Mercier
Chief Commercial & Corporate Affairs Officer, Gilead Sciences
100 in Enterprise · T-105 in B2B · 5 of 43 in Healthcare & Pharma
Top signals: Byline in oncodaily.com (Sep 21); Quoted in trinidadexpress.com (Sep 20)
- Johanna Mercier: A New Pathway for HIV Prevention Across the Americas · oncodaily.com · Sep 21, 2026
- More access to HIV drugs · trinidadexpress.com · Sep 20, 2026
Score breakdown
Measures on a 0 to 100 scale against this month's base of 2,056 CMOs.
45.5 out of 100: the weighted sum of the measures below.
- Visibility 22.5
How much the press wrote about them. An interview or a column counts in full, a quote in a story about the company counts a little, a passing mention or a press release counts zero. Big-company coverage is scaled down so the employer's brand does not carry the person.
- Engagement 99.8
How people respond to their LinkedIn posts: the median post, both in absolute terms and per 1,000 followers, so a huge account does not win by size alone.
- Authority 37.2
The longer track record: press over the past year with older pieces fading, plus awards and major lists.
- AI recall 63.8
Whether AI assistants know who they are without searching the web, asked several times per model and graded by a separate check. Wrong answers do not count.
- Consistency 12.1
Showing up steadily: active weeks on LinkedIn and months with press, on a square-root curve, so posting three times a day does not help.
LinkedIn, last 90 days
- Followers
- 5,782
- Own posts
- 1
- Active weeks of 13
- 1
- Median engagement per post
- 1,247
Engagement is reactions + 2 × comments + 3 × reposts on the person's own posts; reposts of company content are not counted. LinkedIn profile.
Press, awards and talks
Earned coverage from the last 12 months that we confirmed is about Johanna Mercier, not a namesake. Each item links to the source. Press releases and company newsrooms are not counted.
- ColumnT3 Johanna Mercier: A New Pathway for HIV Prevention Across the Americas (opens in a new tab) · oncodaily.com
- QuotedT2 More access to HIV drugs (opens in a new tab) · trinidadexpress.com
- QuotedT3 Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances (opens in a new tab) · Yahoo Finance
Rank history starts with this chart. From the next chart on, this page shows each month's rank and range.